News by Subject Medicine & Health

For years, scientists have been trying to solve a medical mystery: Why do people with diabetes have an increased risk of developing some forms of cancer? Today, researchers report a possible explanation for this double whammy. They found that DNA sustains more damage and gets fixed less often when blood sugar levels are high, thereby increasing cancer risk. The researchers will present their results at the American Chemical Society Fall 2019 National Meeting & Exposition.

Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively. A recent study by researchers at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences reveals global and drug-specific cellular effectors needed for TPD. The results have now been published in the scientific journal Molecular Cell.

University of Calgary researchers at the Cumming School of Medicine (CSM) led by Dr. Donna Senger, PhD, Dr. Paul Kubes, PhD, and Dr. Stephen Robbins, PhD have discovered a new way to stop harmful inflammation in the lungs due to sepsis and injury. They found a molecule, present during inflammation that binds to white blood cells allowing them to pass from the blood stream into the tissue and cause severe damage.

An international team of researchers led by Yale University, University of Iowa, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has discovered a new pathway that may improve success against an incurable type of children's brain cancer. The study results, published today in Nature Communications, suggest that scientists have identified a unique way to disrupt the cellular process that contributes to Diffuse Intrinsic Pontine Gliomas (DIPG).

First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.

A Ludwig Cancer Research study has uncovered a novel vulnerability in tumors that are driven by a common cancer gene known as MYC. Such cancers, it found, are highly dependent on the cell's machinery for making fats and other lipids.